Open AccessHigh‐dose‐rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome
Author(s) -
Strouthos Iosif,
Karagiannis Efstratios,
Zamboglou Nikolaos,
Ferentinos Konstantinos
Publication year - 2022
Publication title -
cancer reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.261
H-Index - 5
ISSN - 2573-8348
DOI - 10.1002/cnr2.1450
Subject(s) - prostate cancer , brachytherapy , medicine , dose rate , medical physics , radiosurgery , external beam radiotherapy , external beam radiation , broad spectrum , radiation therapy , oncology , radiology , nuclear medicine , cancer , chemistry , combinatorial chemistry
Background High‐dose‐rate brachytherapy (HDR BRT) has been enjoying rapid acceptance as a treatment modality offered to selected prostate cancer patients devoid of risk group, employed either in monotherapy setting or combined with external beam radiation therapy (EBRT) and is currently one of the most active clinical research areas. Recent findings This review encompasses all the current evidence to support the use of HDR BRT in various clinical scenario and shines light to the HDR BRT rationale, as an ultimately conformal dose delivery method enabling safe dose escalation to the prostate. Conclusion Valid long‐term data, both in regard to the oncologic outcomes and toxicity profile, support the current clinical indication spectrum of HDR BRT. At the same time, this serves as solid, rigid ground for emerging therapeutic applications, allowing the technique to remain in the spotlight alongside stereotactic radiosurgery.